About this trial
Pivotal trial to evaluate the safety and clinical efficacy of the VDyne System for the treatment of symptomatic severe or greater tricuspid regurgitation.
Eligibility criteria
Qualifiers
Age ≥18 years old
Subject is willing and able to comply with all study evaluations and provide consent
Subject must agree not to participate in any other clinical trial for a period of one year following index procedure
New York Heart Association (NYHA) Functional Class II, III, or IV and ambulatory
Disqualifiers
Subject unable or unwilling to comply with study required testing and follow-up visits
Subject is currently participating in another clinical trial (drug, biologic, or device) that has not yet completed its primary endpoint or is likely to interfere with this study
Pregnant, lactating subjects, and /or those who plan pregnancy in the period up to one year following index procedure.
Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anticoagulation, etc.) which cannot be adequately managed medically
Trial design
Treatments tested in this trial
- Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne System
- Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System